Effects of recombinant human interleukin-6 alone and in combination with recombinant interleukin-1 alpha and tumor necrosis factor alpha on antibacterial resistance in mice.
In this study, recombinant human interleukin-6 (rIL-6) was tested for its ability to alter the resistance of mice to experimental Listeria monocytogenes infection. Single bolus or repeated injections of rIL-6 by itself did not increase antilisteria resistance. When rIL-6 was injected in combination with suboptimal concentrations of rIL-1 alpha and tumor necrosis factor alpha (rTNF-alpha), it did not augment their abilities to mediate protection in the spleen and had a marginal effect on the level of protection in the liver. Injection of rIL-6 together with protective doses of rIL-1 alpha did not diminish the protection stimulated by the latter. Unlike rIL-1 alpha and recombinant tumor necrosis factor alpha, rIL-6 appears to have little ability to elevate antibacterial resistance.
Czuprynski
C J
CJ
Department of Pathological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison 53706.
Haak-Frendscho
M
M
Maroushek
N
N
Brown
J F
JF
D000818:Animals; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007275:Injections, Intravenous; D007375:Interleukin-1 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000008:administration & dosage / Q000627:therapeutic use*; D008089:Listeria monocytogenes / Q000187:drug effects / Q000276:immunology; D008088:Listeriosis / Q000276:immunology / Q000517:prevention & control*; D008099:Liver / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha